| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CLDX | Common Stock | Options Exercise | $259,500 | +25,000 | +71% | $10.38 | 60,128 | 30 May 2024 | Direct | |
| transaction | CLDX | Common Stock | Sale | $1,191,774 | -35,000 | -58% | $34.05 | 25,128 | 30 May 2024 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CLDX | Incentive Stock Option (Right to Buy) | Options Exercise | $0 | -25,000 | -24% | $0.000000 | 80,600 | 30 May 2024 | Common Stock | 25,000 | $10.38 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.69 to $34.55 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
| F2 | 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |